BETA
Your AI-Trained Oncology Knowledge Connection!
Oncology On the Go With ASTCT Talks
CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025
An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.
Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia
Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.
Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting
Shernan Holtan, MD, and Rahul Banerjee, MD, FACP, discussed various trials of significance shared as posters and presentations at the 2025 Tandem Meeting.
Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases
A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.
Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups
Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.
